WO2026136830A1 - Anticorps anti-fcrn et leurs méthodes d'utilisation - Google Patents

Anticorps anti-fcrn et leurs méthodes d'utilisation

Info

Publication number
WO2026136830A1
WO2026136830A1 PCT/US2025/060585 US2025060585W WO2026136830A1 WO 2026136830 A1 WO2026136830 A1 WO 2026136830A1 US 2025060585 W US2025060585 W US 2025060585W WO 2026136830 A1 WO2026136830 A1 WO 2026136830A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
acid sequence
amino acid
differs
amino acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2025/060585
Other languages
English (en)
Inventor
Jordan Tsai
Vahe Bedian
Kirk BERTELSEN
Rachel KAPLAN
Hussam Hisham Shaheen
Rita Leitão Landeiro VAZ
Jason Zee Seug OH
Byong Ha Kang
Yuqi Liu
Fernando Jorge Neto MARTINS
Mariana Carvalho MUGA
Maria Inês DE CASTRO SILVA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Paragon Therapeutics Inc
Original Assignee
Paragon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paragon Therapeutics Inc filed Critical Paragon Therapeutics Inc
Publication of WO2026136830A1 publication Critical patent/WO2026136830A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente divulgation concerne, entre autres, des anticorps et des fragments d'anticorps qui se lient au récepteur Fc néonatal (FcRn). L'invention concerne également des compositions pharmaceutiques comprenant les protéines modifiées de l'invention et des méthodes d'utilisation de celles-ci.
PCT/US2025/060585 2024-12-20 2025-12-19 Anticorps anti-fcrn et leurs méthodes d'utilisation Pending WO2026136830A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202463737467P 2024-12-20 2024-12-20
US63/737,467 2024-12-20

Publications (1)

Publication Number Publication Date
WO2026136830A1 true WO2026136830A1 (fr) 2026-06-25

Family

ID=98601978

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2025/060585 Pending WO2026136830A1 (fr) 2024-12-20 2025-12-19 Anticorps anti-fcrn et leurs méthodes d'utilisation

Country Status (1)

Country Link
WO (1) WO2026136830A1 (fr)

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015167293A1 (fr) * 2014-04-30 2015-11-05 Hanall Biopharma Co., Ltd. Anticorps se liant à fcrn pour le traitement de maladies auto-immunes
WO2016123521A2 (fr) * 2015-01-30 2016-08-04 Momenta Pharmaceuticals, Inc. Anticorps fcrn et leurs procédés d'utilisation
AU2016262100A1 (en) * 2015-05-12 2017-12-21 Syntimmune, Inc. Humanized affinity matured anti-FcRn antibodies
US10280207B2 (en) * 2013-06-20 2019-05-07 Hanall Biopharma Co., Ltd. FcRn-specific human antibody and composition for treatment of autoimmune diseases
AU2014350257B2 (en) * 2013-11-13 2020-04-02 Ucb Biopharma Sprl Antibodies specific to FcRn
CN114728180A (zh) * 2019-11-19 2022-07-08 依牧诺万科学有限公司 使用抗FcRn抗体治疗温性自身免疫性溶血性贫血的方法
WO2023030501A1 (fr) * 2021-09-03 2023-03-09 舒泰神（北京）生物制药股份有限公司 Anticorps capable de reconnaître de manière spécifique fcrn et son utilisation
CN117693523A (zh) * 2021-08-13 2024-03-12 舒泰神（北京）生物制药股份有限公司 特异性识别fcrn的抗体及其用途
CN119013043A (zh) * 2022-05-30 2024-11-22 韩兀生物制药股份有限公司 具有改善的稳定性的抗FcRn抗体或其抗原结合片段

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10280207B2 (en) * 2013-06-20 2019-05-07 Hanall Biopharma Co., Ltd. FcRn-specific human antibody and composition for treatment of autoimmune diseases
AU2014350257B2 (en) * 2013-11-13 2020-04-02 Ucb Biopharma Sprl Antibodies specific to FcRn
WO2015167293A1 (fr) * 2014-04-30 2015-11-05 Hanall Biopharma Co., Ltd. Anticorps se liant à fcrn pour le traitement de maladies auto-immunes
WO2016123521A2 (fr) * 2015-01-30 2016-08-04 Momenta Pharmaceuticals, Inc. Anticorps fcrn et leurs procédés d'utilisation
AU2016262100A1 (en) * 2015-05-12 2017-12-21 Syntimmune, Inc. Humanized affinity matured anti-FcRn antibodies
CN114728180A (zh) * 2019-11-19 2022-07-08 依牧诺万科学有限公司 使用抗FcRn抗体治疗温性自身免疫性溶血性贫血的方法
CN117693523A (zh) * 2021-08-13 2024-03-12 舒泰神（北京）生物制药股份有限公司 特异性识别fcrn的抗体及其用途
WO2023030501A1 (fr) * 2021-09-03 2023-03-09 舒泰神（北京）生物制药股份有限公司 Anticorps capable de reconnaître de manière spécifique fcrn et son utilisation
CN119013043A (zh) * 2022-05-30 2024-11-22 韩兀生物制药股份有限公司 具有改善的稳定性的抗FcRn抗体或其抗原结合片段

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PETER HANS-HARTMUT ET AL: "Targeting FcRn for immunomodulation: Benefits, risks, and practical considerations", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1 September 2020 (2020-09-01), United States, pages 479 - 491.e5, XP055849412, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471860/pdf/main.pdf> [retrieved on 20211008], DOI: 10.1016/j.jaci.2020.07.016 *
RUDIKOFF S ET AL: "Single amino acid substitution altering antigen-binding specificity.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES (PNAS) NATIONAL ACADEMY OF SCIENCES, vol. 79, no. 6, 1 March 1982 (1982-03-01), pages 1979 - 1983, XP002683593, ISSN: 0027-8424, DOI: 10.1073/PNAS.79.6.1979 *

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 25845844

Country of ref document: EP

Kind code of ref document: A1